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METHODS:We identified patients hospitalized for ACS-PCIwith continuous enroll-
ment in MarketScan databases for  6 months before admission and 60 days after
discharge, without history of stroke or transient ischemic attack. Pharmacy dis-
pensing records were searched to determine the first, if any, thienopyridine dis-
pensed within 60 days after discharge. Demographic characteristics, medical and
treatment history during the 6 months prior to the hospitalization were compared
for patients filling prescriptions of clopidogrel, prasugrel, or neither. RESULTS: A
total of 39,953 patients were eligible for the analysis; 29,900 (74.8%) filled clopi-
dogrel prescriptions, 5,243 (13.1%) filled prasugrel prescriptions, and 4,810 (12.0%)
filled no thienopyridines within 60 days after ACS-PCI. Patients filling prasugrel
were younger (mean age 55.9 vs. 60.9, P0.0001), more likely to be male (78.9% vs.
72.2%, P0.0001), and from theMidwest (38.3% vs. 33.9%, P0.0001) comparedwith
clopidogrel users. Patients filling prasugrel had higher percentage of ST elevation
myocardial infarction (STEMI) during the hospitalization than clopidogrel (40.7%
vs. 33.3%, P0.0001). Charlson Comorbidity Index (CCI) was low (0-1) for more
prasugrel than clopidogrel users (85.9% vs. 80.2%, P0.0001); prevalence of many
comorbidities was also lower among prasugrel users. In contrast, patients with
no thienopyridine after ACS-PCI were older (mean age 62.2), more likely to have
high (2) CCI (25.5%, P0.0001), less likely to have STEMI (25.6%, P0.0001) and
a higher prevalence of many comorbidities than patients taking clopidogrel.
CONCLUSIONS: Patients filling no thienopyridine prescription following ACS-PCI
were older and had more comorbidities than patients filling clopidogrel prescrip-
tions. Patients filling prasugrel prescriptions tended to be younger and have fewer
comorbidities than thosewith clopidogrel, whichmay reflect lower bleeding risk of
this ACS-PCI population.
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ASSESSING THE EVIDENCE ASSIMILATION TIME FRAME: FROM TRIALS TO
TREATMENT GUIDELINES IN CARDIOVASCULAR DISEASE
Hanger M, Mahendraratnam N, Mitchell K
Avalere Health LLC, Washington, DC, USA
OBJECTIVES: The Institute of Medicine estimates that 17 years elapse between
phase III study completion and a new treatment’s full integration into clinical
practice. Recognizing that clinical practice guidelines (CPGs) are an important
source of information for clinicians as they integrate new treatments into routine
practice, we sought to understand the time it takes for CPGs to release recommen-
dations on novel therapies.METHODS:We conducted case analyses in CVD, a high
burden therapeutic area with numerous treatment options and well-established
guideline development processes. We selected 4 antithrombotic therapies intro-
duced over the past 15 years: ticagralor, dabigatran, prasugrel, and clopidogrel. For
each drug we captured key dates to assess the time interval between release of
registration trial data and inclusion in CPGs. The guidelines explored were the
leading US and EU references for the relevant indication, and “inclusion in CPGs”
referred to the presence of a class- or product-specific recommendation (October,
2011). RESULTS: Across 3 products, the interval from data release to CPG inclusion
ranged from 4 to 18 months (mean 25 months) in the United States, and 13 to 46
months (mean 29 months) in the EU. Limitations of the analysis include no dab-
igatran-relevant recommendations to date in the EU guidelines reviewed, and no
ticagrelor-relevant recommendations to date in the US guidelines reviewed. Addi-
tionally, ticagralor appeared in EU guidelines 2 months prior to regulatory
approval. CONCLUSIONS: Our observational analysis shows that the time it takes
for CPGs to incorporate new therapies varies, even within the same therapeutic
area and the same guideline developers. Future research will expand this inquiry
into other therapeutic areas and also explore various product- and market-level
factors that may affect time to CPG inclusion. While guidelines organizations work
to streamline review processes, manufacturers should improve their understand-
ing of revision timelines to maximize the impact of data release.
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USING INTERNATIONAL HTA GUIDELINES TO INFORM UK HEALTH CARE
DECISION-MAKING: A CASE STUDY OF TICAGRELOR IN COMBINATION WITH
LOW-DOSE ASPIRIN FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
Dequen P1, Sutton AJ1, McGrath C2, Abrams K1
1University of Leicester, Leicester, UK, 2Pfizer Ltd., Tadworth, Surrey, UK
BACKGROUND: Several HTA agencies around the world have published compre-
hensive HTA guidelines to help authors adhere to the principles and methods of
HTA. Many have also embraced recent methodological developments in compar-
ative effectiveness research, such as indirect and mixed treatment comparisons,
and recommend their use when head-to-head evidence is not available. Differ-
ences exist, however, between these guidelines and how these are interpreted
especially in terms of evidential andmethodological requirements.OBJECTIVES:A
case study was conducted to evaluate the impact of different evidence synthesis
methods, as recommended by HTA agencies, on the effectiveness and cost-effec-
tiveness of new medicines in the UK.METHODS: Using a reconstructed economic
model based on the NICE technology appraisal for ticagrelor (TA236), different
evidence base andmeta-analysis methods were used, in accordance with country-
specific HTA guidelines and existing assessment reports (i.e. CADTH (Canada), CVZ
(The Netherlands), PBAC (Australia)), to estimate the relative effectiveness and
ICER of ticagrelor compared to clopidogrel and prasugrel for the treatment of acute
coronary syndromes. Differences in evidence identification and study selection,
evidence synthesis, and clinical effectiveness model inputs were evaluated.
PRELIMINARY RESULTS: Whilst CADTH and CVZ included a published indirect
comparison between ticagrelor and prasugrel in their evidence review; NICE re-
garded the use of indirect evidence as inappropriate and PBAC did not consider
prasugrel as a relevant comparator. Such differences in clinical evidence consid-
erations, and methods used call into question recent efforts to promote interna-
tional HTA harmonisation. In addition, the uncertainty in the results estimated in
our model demonstrated the importance of appropriately defining and measuring
(relative) efficacy inputs inHTA to ensure optimal health policies are implemented.
CONCLUSIONS: Since 2011, ticagrelor is recommended for use in the United King-
dom; however, the Canadian Expert Drug Advisory Committee recommended that
ticagrelor not be listed in publicly funded drug plans in Canada.
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AN ASSESSMENT OF THE MODIFIED RANKIN SCALE AS A STROKE OUTCOME
MEASURE IN ECONOMIC ANALYSES OF ACUTE ISCHEMIC STROKE OUTCOMES
Burton KR, Beaton DE
University of Toronto, Toronto, ON, Canada
OBJECTIVES: An effective measurement tool is required to assess the economic
effects of acute ischemic stroke (AIS) imaging interventions and to determine how
themagnitude of AIS-attributable impairment changes over time so that thesemay
be incorporated into economic analyses. The modified Rankin scale (mRS) is the
most prevalently used measure of AIS outcomes however it has generated skepti-
cism, concern and confusion regarding the results of stroke outcome studies. This
study assesses all clinimetric properties of the mRS and outlines improvement
opportunities.METHODS: ThemRS was analyzed using a set of clinimetric assess-
ment instruments including the Bombardier sensibility assessment tool and Bea-
ton responsiveness guidelines. Each clinimetric domain was evaluated, namely,
measure development; item generation; measure administration; sensibility; reli-
ability; validity; and responsiveness. RESULTS: The mRS displayed many short-
comings including: 1) vague definition of concept measured; 2) lack of item gener-
ation rigor; 3) compromised face validity; 4) no evidence of validity and reliability
among AIS patients; and 5) inadequate study of responsiveness due to arbitrary
choices of clinically important differences for comparison scales. CONCLUSIONS:
The mRS is a flawed instrument for estimating AIS outcomes. Minimally, high
quality, adequately powered de novo assessments of its validity, reliability and
responsiveness should be undertaken. Preferably, a new AIS outcome measure to
measure should be developed by following the detailed recommendations within
each of the clinimetric properties sections of this assessment. This ideal AIS out-
come measure could be applied to AIS outcome studies resulting in a facilitation,
rather than obfuscation, of efforts to reduce the burden of AIS.
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CAN MODERN PSYCHOMETRIC APPROACHES IMPROVE ROLE FUNCTIONING
ASSESSMENT IN ACUTE CORONARY SYNDROME PATIENTS? A PRELIMINARY
TRACE-CORE ANALYSIS
Anatchkova M1, Bjorner JB2
1UMMS, Worcester, MA, USA, 2National Institute for the Working Environment, Copenhagen,
Denmark
OBJECTIVES: Item response theory (IRT) combined with computer adaptive testing
(CAT) can improve assessment of self-reported measures by reducing measure-
ment error and respondent burden. We previously used IRT to develop an item
bank of health impact on role functioning (RF) in 3 areas (family, social, occupa-
tional).We tested the validity of a simulated 4-itemCATbased on 10 items fromour
previously-developed bank in acute coronary syndrome (ACS) patients and com-
pared its performance with 2 established SF-36 scales - role physical (RP) and role
emotional (RE).METHODS: Adults (n759) in Worcester, MA and Macon, GA were
interviewed during an ACS hospitalization for the TRACE-CORE (Transitions, Risk,
and Actions in Coronary Events: Center for Outcomes Research and Education)
study. Ten questions from the RF item bank were administered; we assessed their
construct validity using factor analysis. We produced a 4-item CAT using simula-
tions with the 10-item data. We compared score accuracy and ability to discrimi-
nate between groups based on levels of self-reported general health (SF-36), de-
pression (PHQ9) and anxiety (GAD7) for the 10 items, the CAT and the SF-36 role
scales. RESULTS: Average patient age was 61.111.6 years, with 64.8% men, 76%
non-Hispanicwhite, 13%African-American.We confirmed the construct validity of
the 10-bank items. The CAT improvedmeasurement precision and expandedmea-
surement range by 0.5 SD versus the SF36 RP. All measures discriminated across
levels of general health, depression, and anxiety (p 0.0001). The instruments
showed high agreement on the mean score for each subgroup, but the CAT scores
had lower SDs. Relative validity coefficients suggest that CAT discriminated better
than the SF36 RP and RE scales. CONCLUSIONS: Use of CAT improved assessment
accuracy and discrimination among pre-defined groups, suggesting modern psy-
chometric approach leads to practical advantages in assessment. Results will fur-
ther be validated with clinical criteria and predictive analysis.
PCV124
COMBINING ELECTRONIC HEALTH RECORDS AND PATIENT-REPORTED
INFORMATION IN THE UK: PRELIMINARY RESULTS FROM WASPS (WALES
SAIL  PRO STUDY)
Cascade E1, Ford D2, Nixon M3, Brooks C2, Heaven M2
1MediGuard.org, Rockville, MD, USA, 2Swansea University, Swansea, UK, 3Quintiles Global
Consulting, Bracknell, Berkshire, UK
OBJECTIVES: As demand for real-world data increases, the need to adopt more
time and cost-efficient research methods will grow. Direct-to-patient studies (di-
rect patient recruitment without physician sites) are a novel, efficient approach
gaining proof in the United States. This study’s objective was to deploy a direct-to-
patient observational study in the UK including both patient-reported and elec-
tronic health data. METHODS: In October/November 2011, UK MediGuard.org
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members with a cholesterol marker in their profile were invited to participate via
email; enrollment was supplemented with digital outreach. Interested individuals
clicked a link to access study information and screen based on self-reported diag-
nosis and willingness to have data linked to the SAIL warehouse. Study subjects
completed an on-line questionnaire and provided identifiers to be used only for
data linkage. The SAIL system’s NHS Trusted Third Party converted study identifi-
ers into pseudo-identifiers allowing the linkage of patient-reported data with elec-
tronic health data. RESULTS: A total of 240 enrolled within 6 weeks: 98 fromMedi-
Guard and 142 through other digital channels. NHS matched 226 of 240 (94%) to a
pseudo-identifier (69 exactly, 157with probability0.9). A total of 91 of 226matched
(41%) had at least one primary care record in SAIL and nearly all (89 of 91, 98%) had
data suggesting a cholesterol problem.Matching cholesterol test dates (6months)
were located for 66 of 89 (74%, Spearman correlation0.786, p0.0001) and there
was a high positive correlation of total cholesterol values amongst the 1/3 of pa-
tients able to self-report data (n28, Pearson correlation0.785, P0.0001). Addi-
tional analyses exploring markers that predict patient’s ability to self-report are
underway. CONCLUSIONS: This study demonstrates the feasibility of linking pa-
tient reported data with electronic health information. UK individuals are inter-
ested in participating, provide truthful information, and their patient-reported
data can be linked to electronic information in the SAIL warehouse in Wales, thus
offering new research possibilities.
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IMPACT OF POSTSURGICAL OPIOID USE AND ILEUS ON ECONOMIC OUTCOMES
IN GASTROINTESTINAL SURGERIES
Oderda G1, Robinson SB2, Gan TJ3, Scranton R4, Pepin J5, Ramamoorthy S6
1University of Utah, Salt Lake City, UT, USA, 2Premier Healthcare Alliance, Charlotte, NC, USA,
3Duke University Health System, Durham, NC, USA, 4Pacira Pharmaceuticals, Parsippany, NJ,
USA, 5Seton Medical Center Williamson, Round Rock, TX, USA, 6University of California San
Diego, La Jolla, CA, USA
OBJECTIVES: To determine the relationship between postsurgical opioid use
through morphine equivalent dose (MED) and ileus was assessed in patients un-
dergoing commonGI surgeries, and the impact of ileus on length of stay (LOS), total
visit cost, and 30-day readmissions.METHODS: The Premier database was queried
to identify adult inpatients discharged between 2008 and 2010 who received post-
surgical opioids following open colectomy, laparoscopic colectomy or cholecystec-
tomy. Ileus was identified using ICD-9 diagnosis codes and postsurgical (MED) was
calculated. Descriptive statistics including the outcomes of LOS, total visit cost, and
30-day readmissionwere obtained. For comparing patients with andwithout ileus,
t-tests for continuous variables and chi-squared tests for categorical variableswere
used (alpha 0.05). RESULTS: There were 138,068 patients, average age of 56.8 (SD
18.5) that met the study criteria. Overall, 10.3% of patients had an ileus, ranging
from 3.2% in laparoscopic cholecystectomy to 20.6% in open colectomy. The unad-
justed mean LOS (7.3 days p0.0001), total visit cost ($15,928 p0.0001), and
readmissions (5.9% p0.0001) were higher for patients with ileus compared to
those without ileus. Of note, the total visit costs were 3 times higher among pa-
tients experiencing an ileus after laparoscopic cholecystectomies compared to 2
times greater for other GI procedures complicated by ileus, than patients without
ileus. Patients with higher (abovemedian) MED compared to lower (belowmedian)
MED had a 2 fold greater odds of ileus (OR 2.0 95% CI 1.92 – 2.06; p 0.0001).
CONCLUSIONS: Occurrence of ileus significantly increased the total cost across all
GI surgeries even in surgeries where the incidence of ileus is less common. In this
study, higher dosages of opioids are associated with the incidence of ileus; more
research is needed to determine whether strategies to decrease opioid use im-
proves outcomes and reduces ileus.
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ASSESSMENT OF RISK OF HEPATOTOXICITY ASSOCIATED WITH ANTITHYROID
DRUGS IN PATIENTS WITH HYPERTHYROIDISM
Wang MT, Lee WJ
National Defense Medical Center, Taipei, Taiwan
OBJECTIVES: To quantify the incidence of hepatotoxicity associated with antithy-
roid drugs and analyze the relative hepatotoxicity risk of methimazole (MMI) and
carbimazole (CBM) compared to propylthiouracil (PTU) among patients with
hyperthyroidism. METHODS: A retrospective population-based cohort study was
conducted by analyzing data from the Taiwan National Health Insurance Research
Databases between January 1, 2004 andDecember 31, 2008. Patients diagnosedwith
hyperthyroidism (ICD-9-CM codes 242.xx, 775.3) and initially receiving antithyroid
drugs were identified as the study cohort, in which MMI/CBM and PTU users were
further specified. The two groups were followed up to observe the occurrence of
hepatotoxic events, including jaundice, cholestasis, noninfectious hepatitis, acute
liver failure, and liver transplant. Crude incidence rates of the hepatotoxicity per
1000 person-years were calculated. Cox proportional hazard models were em-
ployed to estimate crude and adjusted hazard ratios (HRs) of hepatotoxicity risks
for MMI/CBM relative to PTU. RESULTS: The study cohort comprised a total of
71,379 patientswith hyperthyroidism. The hepatitis outcomewas observed to have
the highest incidence in bothMMI/CBM and PTU users, with a rate of 11.44 and 9.89
events per 1000 person-years, respectively. The comparative risk analyses indi-
cated that use of MMI/CBM exerted a significantly increased risk of hepatitis than
use of PTU (adjusted HR, 1.23; 95% CI, 1.03-1.47). Additionally, MMI/CBM prescribed
at an average daily dose greater than 10 mg further enhanced the risk of jaundice
(adjusted HR, 1.99; 95% CI, 1.13-3.49) and hepatitis (adjusted HR, 2.33; 95% CI, 1.93-
2.82) to a larger degree than any use of PTU. CONCLUSIONS: Hepatitis is the most
frequently occurring hepatotoxicity outcome for both MMI/CBM and PTU users.
Notably, MMI/CBM is associated with a higher risk of hepatitis than PTU in a dose-
dependent manner. Health care professionals should be vigilant to the symptoms
of hepatitis for patients prescribed antithyroid drugs, especially for those receiving
higher doses of MMI/CBM.
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VALIDATION OF ALGORITHMS TO IDENTIFY DIVERTICULITIS THROUGH
ELECTRONIC MEDICAL RECORDS IN KAISER PERMANENTE SOUTHERN
CALIFORNIA (KPSC)
Kawatkar AA1, Chu LH1, Chen W1, Yen L2, Erder MH2, Hodgkins P2, Iyer R1, Longstreth G3
1Southern California Permanente Medical Group, Pasadena, CA, USA, 2Shire Development, LLC,
Wayne, PA, USA, 3Kaiser Permanente, San Diego, CA, USA
OBJECTIVES: To develop and validate algorithms that can identify diverticulitis
patients with high reliability through the use of electronic medical records (EMRs).
METHODS:UsingKPSC EMRs of adults (18 years old)with ICD-9 diagnosis codes of
diverticulitis (562.11, 562.13) between January 1, 2008 and August 30, 2009, we gen-
erated random samples for pilot-testing (N700) and validation purposes
(N1,300) respectively. Both samples were stratified by inpatient (IP), emergency
room (ER), and outpatient (OP) treatment settings. For each setting, we constructed
and analyzed 10 different algorithms based on EMR variables such as diverticulitis
diagnosis code, antibiotics use, computed tomography (CT), and prior diverticulo-
sis diagnosis. Evidence of diverticulitis was verified and confirmed throughmanual
chart review by trained research associates. Agreement between each EMR algo-
rithm and chart confirmation was compared by estimating sensitivity and positive
predictive value (PPV). We defined acceptable sensitivity and PPV as 80%.
RESULTS: ICD-9 diagnosis in combinationwith use of antibiotics within 7 dayswas
the most accurate algorithm to identify diverticulitis in patients treated in OP and
ER settings. For those admitted inpatients, the most accurate algorithm was the
combination of diagnosis code with lower abdominal CT recorded within 7 days of
diagnosis. In the pilot-testing sample, sensitivity and PPV were (94.7%, 81.7%),
(79.1%, 88.7%), and (86.7%, 82.8%) for OP, ER, and IP, respectively. In the validation
sample, sensitivity and PPV remained very high: (85.6%, 96.1%), (91.5%, 94.4%), and
(79.1%, 81.2%) for OP, ER, and IP, respectively. CONCLUSIONS: The KPSC algorithms
developed to identify diverticulitis cases using EMR resulted in high accuracy for
three different treatment settings. The validity of these algorithms should be fur-
ther evaluated in other systems.
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TREATMENT PATTERNS OF MEDICARE PATIENTS WITH ULCERATIVE COLITIS
INITIATING TUMOR NECROSIS FACTOR THERAPY: APPLICATION OF A DATA
VISUALIZATION TOOL
Baser O1, Wang L2, Xie L1, Yuce H3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3New York City College of Technology-CUNY / STATinMED Research, New
York, NY, USA
OBJECTIVES: In a field wheremany disciplines, such as clinicians, epidemiologists,
economists and statisticians, interact frequently, a tool to communicate drug
treatment patterns clearly and effectively through graphical means is a necessity-
.Using data visualization techniques, we aim to clearly present treatment patterns
among patients with ulcerative colitis (UC). METHODS: Using the 100% national
Medicare data with Part D information, patients over age 65 with at least one UC
diagnosis were selected for the study. We identified patients who initiated therapy
with tumor necrosis factor (TNF) and non-TNF therapies. For 2 years after the
initiation of biologics, we determined the treatment patterns such as switching to
another TNF, non-TNF, and discontinuation. Using a processing language, we cre-
ated a data visualization tool to demonstrate how patients change their drug pat-
tern after first, second and third switches. RESULTS: A total of 1643 UC patients
initiated their therapy with a TNF agent. 3.47% of these patients switched to an-
other TNF, 1.40% switched to a non-TNF, 61.17% discontinued their therapy, and
33.96% continued their initial therapy. Among patients who switched to another
TNF, 49.12% remained on the switched therapy, 40.35% discontinued therapy,
10.53% switched to another TNF, and no patients switched to a non-TNF. 2,628 UC
patients initiated their therapy with a non-TNF, of which 0.49% switched to an
anti-TNF, 0.19% switched to non-TNF, 97.98% discontinued therapy and 1.33% con-
tinued their initial therapy. CONCLUSIONS: Treatment patterns can be difficult to
present, especially when analyzing several data years and among various switch-
ing patterns. Data visualization tools can help researchers present complicated
results, such as treatment patterns, effectively to a varied audience.
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VISUALIZING TREATMENT PATTERNS OF MEDICARE PATIENTS WITH CROHN’S
DISEASE WHO INITIATED TUMOR NECROSIS FACTOR THERAPY
Baser O1, Wang L2, Xie L1, Yuce H3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3New York City College of Technology-CUNY / STATinMED Research, New
York, NY, USA
OBJECTIVES: In health outcomes research, wheremany different disciplines inter-
act frequently, a tool to communicate treatment patterns clearly and effectively
through graphical means is a necessity. Using data visualization techniques, we
aimed to present treatment patterns of patients with Crohn’s disease in a visual
manner. METHODS: This study used 100% national Medicare data with Part D
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